Connect with us

Technology

In-Vitro Diagnostics Instruments Market size is set to grow by USD 52.9 billion from 2024-2028, Growing geriatric population boost the market, Technavio

Published

on

NEW YORK, July 31, 2024 /PRNewswire/ — The global in-vitro diagnostics instruments market size is estimated to grow by USD 52.9 billion from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of 9.29% during the forecast period. Growing geriatric population is driving market growth, with a trend towards potential opportunities for physician office laboratories (POL). However, strained laboratory budgets and lowering reimbursements affecting instrument sales poses a challenge. Key market players include Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc..

Get a detailed analysis on regions, market segments, customer landscape, and companies- View the snapshot of this report

In-Vitro Diagnostics Instruments Market Scope

Report Coverage

Details

Base year

2023

Historic period

2017 – 2021

Forecast period

2024-2028

Growth momentum & CAGR

Accelerate at a CAGR of 9.29%

Market growth 2024-2028

USD 52.9 billion

Market structure

Fragmented

YoY growth 2022-2023 (%)

8.25

Regional analysis

North America, Europe, Asia, and Rest of World (ROW)

Performing market contribution

North America at 33%

Key countries

US, Germany, China, Canada, and UK

Key companies profiled

Abbott Laboratories, Becton Dickinson and Co., Bio Rad Laboratories Inc., bioMerieux SA, Biosino Bio Technology and Science Inc, CPC Diagnostics Pvt Ltd., DAAN Gene Co. Ltd., Danaher Corp., F. Hoffmann La Roche Ltd., Guangzhou Wondfo Biotech Co. Ltd., Hologic Inc., Myriad Genetics Inc., QIAGEN NV, QuidelOrtho Corp., Shanghai Kehua Bio Engineering Co. Ltd, Shenzhen Mindray BioMedical Electronics Co. Ltd, Siemens AG, Sysmex Corp., and Thermo Fisher Scientific Inc.

 

Market Driver

In-Vitro Diagnostics (IVD) instruments market growth is driven by the increasing adoption of Point of Care (POL) testing in primary and outpatient care. POL testing, particularly in infectious disease markers, cardiovascular diseases, and diabetes care, is gaining popularity due to its convenience and quick results. Portable IVD instruments are advancing technically, enabling clinicians to perform tests in-house. The CLIA testing for molecular assays in POL practices is expected to fuel market growth. However, certain regulatory aspects regarding CLIA-waived testing may impact market expansion. Despite these challenges, the global IVD instruments market is projected to experience average growth due to the increasing trend towards POL testing. 

The In Vitro Diagnostics Instruments Market is experiencing significant growth due to the rising demand for accurate and rapid medical tests. With a focus on infectious diseases such as Malaria and Chikungunya, the market is seeing increased adoption of advanced technologies like Next-Generation Sequencing (NGS) for pathogen detection. Laboratory technicians play a crucial role in this sector, handling various samples like blood, serum, plasma, urine, saliva, and tissues. Blood banks, home care settings, pharmaceutical companies, biotechnology firms, academic institutes, and non-communicable disease segments are key end-users. Infectious diseases and chronic conditions including cardiology, gastroenterology, and cancer are major application areas. The aging population and the rise of molecular diagnostics for diseases like Alzheimer’s and various cancers further fuel market expansion. In vitro diagnostics instruments offer efficiency, accuracy, and convenience in the laboratory environment, making them an essential tool for healthcare providers. 

Discover 360° analysis of this market. For complete information, schedule your consultation – Book Here!

Market Challenges

In the In-Vitro Diagnostics Instruments Market, reimbursement policies for diagnostic testing vary across geographies and are trending downward. This puts pressure on hospitals and diagnostic laboratories to reduce expenditure on IVD instruments to maintain revenue. Workforce shortages and lost health insurance cards lead to fewer patient visits and limited testing volumes. Lean laboratories are emerging in some countries, prioritizing essential capital equipment purchases. Reduced reimbursements for certain instruments, such as SMBG in Europe and IVD instruments in the US, impact sales growth. IVD companies respond by focusing on emerging markets and adapting to market conditions. These factors are expected to restrict the growth of the global IVD Instruments Market during the forecast period.The In-Vitro Diagnostics (IVD) Instruments Market is experiencing significant growth due to advances in Next Generation Sequencing, Liquid Biopsy, and Personalized Medicine. Genetic and molecular diagnostic technologies are driving innovation in Clinical Profiles, Companion Diagnostics, and various disease areas such as Hospitals and Healthcare Facilities. IVD equipment in Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, and Cardiac Diseases are in high demand. Challenges include Norovirus, HIV, Lyme disease, and other infectious diseases. Reagents and kits, Software and Services, and Manufacturing Technology are essential components of this market. Diabetes, Oncology, Sexually Transmitted Diseases, and Geriatric Population are key applications. Distribution channels include hypermarkets, pharmacies, drug stores, online providers, standalone laboratories, and Clinical Laboratories. Tropical diseases and Endocrine Disorders are also targeted markets. High blood cholesterol, Heart Disease, Stroke, and Chronic Conditions are significant disease areas.

For more insights on driver and challenges – Request a sample report!

Segment Overview 

This in-vitro diagnostics instruments market report extensively covers market segmentation by 

Product 1.1 Immunochemistry1.2 Clinical microbiology1.3 Molecular diagnostics1.4 OthersEnd-user 2.1 Hospitals and diagnostic laboratories2.2 Academic and research institutes2.3 Home careGeography 3.1 North America3.2 Europe3.3 Asia3.4 Rest of World (ROW)

1.1 Immunochemistry- The In-Vitro Diagnostics (IVD) Instruments Market’s highly automated segment of clinical laboratories holds the largest test volume compared to others. However, the demand for immunochemistry analyzers is declining in the US and Europe due to consolidation in France, late payments from Italy, Spain, and Portugal, and reductions in expenditure in the UK, France, and Germany. In contrast, the rise of rural hospitals in China and India lacking basic diagnostics infrastructure presents a growth opportunity. Over 80 immunoassay analyzer models are available, with manufacturers responding to competition through frequent new launches or analyzer upgrades. Reduced European reimbursement is attributed to delayed spending by some medical laboratories, while the Affordable Care Act (ACA) provides greater certainty for investments. IVDs, like Ortho Clinical Diagnostics’ VITROS immunodiagnostic products for HIV-1+2 detection, aid in early COVID-19 virus detection. Roche Diagnostics received FDA approval for the first HIV-1/HIV-2 qualitative test on cobas 6800/8800 systems. Innovative products and advanced technologies continue to enter the market, intensifying competition during the forecast period.

For more information on market segmentation with geographical analysis including forecast (2024-2028) and historic data (2017-2021) – Download a Sample Report

Research Analysis

In vitro diagnostics refer to medical tests conducted outside of a living organism, using samples of bodily fluids, tissues, or other specimens. These tests play a crucial role in the detection and diagnosis of various diseases, including infectious diseases such as Zika, Malaria, and Chikungunya, as well as chronic conditions like cardiovascular diseases, cancer, and endocrine disorders. The laboratory environment is essential for the accurate and reliable performance of these tests. In vitro diagnostics are used extensively in clinical laboratories to diagnose non-communicable diseases such as heart disease, stroke, high blood cholesterol, and Alzheimer’s disease. Molecular diagnostics and pathogen detection are advanced areas of in vitro diagnostics, offering rapid and accurate results for the diagnosis of various conditions. Laboratory technicians play a vital role in the collection, preparation, and analysis of samples for in vitro diagnostic tests. In vitro diagnostics are used in various medical specialties, including cardiology, gastroenterology, and neurology, to aid in the early detection and treatment of diseases.

Market Research Overview

In Vitro Diagnostics Instruments Market: Overview The In Vitro Diagnostics Instruments Market refers to the industry that produces and supplies diagnostic tools and equipment used in medical laboratories for analyzing samples derived from bodily fluids, tissues, and other specimens. These diagnostic instruments play a crucial role in detecting various diseases, including infectious diseases such as Norovirus, HIV, Lyme disease, and Shigellosis, chronic conditions like diabetes, cardiovascular diseases, cancer, and Alzheimer’s disease, and genetic disorders. The market caters to various end-users, including hospitals, healthcare facilities, pharmacies, drug stores, online providers, standalone laboratories, and clinical laboratories. The In Vitro Diagnostics Instruments Market encompasses a wide range of diagnostic technologies, including Immunodiagnostics, Hematology, Tissue Diagnostics, Clinical Chemistry, Cardiac Diseases, Immune System Disorders, Nephrological Diseases, Gastrointestinal Diseases, and others. The market is segmented into various product categories, including IVD equipment, Diagnostic Technologies, Reagents and Kits, Software and Services, and Molecular Diagnostics. Molecular Diagnostics further includes Next-Generation Sequencing (NGS), Liquid Biopsy, and Personalized Medicine. The market is also influenced by various factors such as the aging population, the rise in non-communicable diseases, and the increasing prevalence of chronic conditions. The In Vitro Diagnostics Instruments Market is driven by the growing demand for early and accurate diagnosis, the increasing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies such as NGS, liquid biopsy, and companion diagnostics. The market is also expected to witness significant growth due to the increasing prevalence of diseases such as diabetes, cancer, and cardiovascular diseases, and the growing awareness and acceptance of genetic testing. The market is highly competitive, with various players offering a wide range of diagnostic instruments and solutions. The market is also witnessing significant innovation, with new technologies and products being developed to address the evolving needs of healthcare providers and patients. Some of the key trends in the market include the increasing use of automation, the integration of artificial intelligence and machine learning, and the growing focus on point-of-care testing. The In Vitro Diagnostics Instruments Market is expected to grow at a significant CAGR during the forecast period, driven by the increasing demand for accurate and timely diagnosis, the growing prevalence of chronic diseases, and the increasing adoption of advanced diagnostic technologies. The market is also expected to be influenced by various factors such as regulatory frameworks, reimbursement policies, and technological advancements. In conclusion, the In Vitro Diagnostics Instruments Market plays a vital role in the healthcare industry by providing accurate and timely diagnosis, enabling personalized medicine, and contributing to better patient outcomes. The market is highly dynamic and is expected to witness significant growth in the coming years, driven by various factors such as the increasing prevalence of chronic diseases, the growing focus on personalized medicine, and the increasing adoption of advanced diagnostic technologies.

Table of Contents:

1 Executive Summary
2 Market Landscape
3 Market Sizing
4 Historic Market Size
5 Five Forces Analysis
6 Market Segmentation

ProductImmunochemistryClinical MicrobiologyMolecular DiagnosticsOthersEnd-userHospitals And Diagnostic LaboratoriesAcademic And Research InstitutesHome CareGeographyNorth AmericaEuropeAsiaRest Of World (ROW)

7 Customer Landscape
8 Geographic Landscape
9 Drivers, Challenges, and Trends
10 Company Landscape
11 Company Analysis
12 Appendix

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 17,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

Contacts

Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/

View original content to download multimedia:https://www.prnewswire.com/news-releases/in-vitro-diagnostics-instruments-market-size-is-set-to-grow-by-usd-52-9-billion-from-2024-2028–growing-geriatric-population-boost-the-market-technavio-302210037.html

SOURCE Technavio

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Technology

Shapiro+Raj Expands Team with Strategic Hires to Accelerate Life Sciences Growth

Published

on

By

CHICAGO, April 7, 2025 /PRNewswire/ — Shapiro+Raj, the #1 Strategic and #12 Most Innovative Insights Consultancy, is excited to announce the addition of four accomplished professionals to its Research and Operations teams. These strategic hires will support the growing demand from Life Sciences clients for compelling insights that help them shape the future, not just respond to it in today’s continually reshaping healthcare landscape.

“These new team members strengthen our commitment to delivering exceptional client outcomes without compromise,” said Zain Raj, Chairman and CEO of Shapiro+Raj. “By combining our AI-forward capabilities with our strength in social and behavioral-sciences-led insights and strategy, we’re helping our clients get to the future faster.”

The new additions driving strategic insights are:

Jill Carnick joins as Insights Director. She brings over 25 years of experience and a proven track record of developing research frameworks to help clients make sound, strategic business decisions that drive brand and business growth.

Yasmeen Elsakary and Bhakya Dhanathiagu join as Insights Executives, supporting integrated learning agendas that provide comprehensive, actionable insights.

Sarah Karim joins the Field & Project Management team as Manager. She will be part of the team that ensures seamless project execution through expert logistics, partner coordination, and operational support.

“These are not just talented professionals; they’re the kind of people who help elevate the entire organization,” said Amir Kapadia, Chief Operating Officer. “Their ability to translate complexity into clarity, and strategy into action, will ensure our clients gain not just insights but a true competitive edge in the market.”

About Shapiro+Raj

Shapiro+Raj, the #1 Strategic and #12 Most Innovative Insights Consultancy partners with Fortune 500 clients to shape the future of business and brands. With deep expertise in the life sciences space, the firm delivers future-forward insights and strategic guidance that drive impact. Shapiro+Raj is headquartered in Chicago, with offices in New York and Pune, India.

For more information, visit www.shapiroraj.com 

View original content to download multimedia:https://www.prnewswire.com/news-releases/shapiroraj-expands-team-with-strategic-hires-to-accelerate-life-sciences-growth-302422283.html

SOURCE SHAPIRO+RAJ

Continue Reading

Technology

LightBox CRE March Index Posts Strongest Reading Since 2022, But Outlook Remains Uncertain

Published

on

By

IRVINE, Calif., April 7, 2025 /PRNewswire/ — LightBox, a leading provider of commercial real estate (CRE) data and technology, today reported that its CRE Activity Index rose sharply to 104.4 in March, marking the highest level since June 2022 and only the second triple-digit reading in nearly three years. The 4.7% month-over-month and 25.2% year-over-year gains point to growing momentum in the CRE sector. But just days after March ended, the market was hit with a fresh wave of uncertainty following last week’s announcement of sweeping new tariffs, injecting renewed volatility into an already uneven economic environment.

“While volatility rattled other parts of the market, March’s index highlights the commercial real estate sector’s resilience,” said Manus Clancy, head of Data Strategy at LightBox. “Rising listings and consistent lender activity show that investors found opportunities, even in this uncertain economic environment.”

The LightBox CRE Activity Index measures national activity across commercial property listings, environmental due diligence, and appraisals—key functions that support CRE transactions and collectively serve as a leading indicator of deal activity. The Index is normalized to account for variations in the number of business days per month, providing a consistent measure of market trends.

March’s triple-digit index reading signals increasing transactional velocity across asset types and geographies. Each of the three core metrics behind the Index reflects a clear trajectory of growth:

Property listings jumped 56% year-over-year, more than double where they were at year-end 2024.
 Phase I environmental site assessments (typically conducted prior to major CRE loans or transactions) rose 3% year-over-year and a more significant 12% over February volume.
 Lender-driven commercial appraisal awards climbed 6% year-over-year and increased by 5% from February.

While equities declined and the 10-year Treasury yield swung sharply in March, LightBox analysis suggests the CRE market may be decoupling from broader market volatility, buoyed by investor interest in income-producing assets and distressed opportunities.

“Commercial real estate deal activity is showing real momentum, with investors reengaging across both distressed and stabilized assets,” said Dianne Crocker, research director at LightBox. “March’s Index reaching a new high is an encouraging sign—but with last week’s sweeping tariff announcement injecting fresh uncertainty into the market, the outlook for April is far less predictable. Volatility is back in play, and that could influence how capital moves in the near term.”

The report highlights that March’s index strength occurred despite mixed economic signals last month: a spike in core PCE inflation, softening consumer sentiment, and concerns over proposed tariffs and supply chain disruption. CRE professionals remain cautiously optimistic, with the industrial, multifamily, and data center sectors continuing to draw the strongest interest amid an otherwise uncertain economic backstop.

“March’s triple-digit reading points to growing momentum, suggesting that CRE may have emerged as a relative safe haven—for now,” emphasized Clancy. “But with uncertainty mounting around global trade, inflation, and labor, whether that status holds will depend on how key economic indicators play out in the months ahead.”

Take a Closer Look at the March Numbers

About LightBox

At LightBox, we are at the forefront of delivering advanced and precise solutions for commercial real estate intelligence. Our dedication to innovation propels real estate professionals forward by providing them with the essential tools required to navigate complex decisions, minimize risk, and boost productivity across the spectrum of real estate operations. LightBox is renowned for its commitment to promoting excellence and fostering connections in the industry, serving an extensive clientele of over 30,000 customers. Our diverse client base spans commercial and government sectors, including but not limited to brokers, developers, investors, lenders, insurers, technologists, environmental advisors, appraisers, and other businesses that depend on geospatial information. To discover more about how LightBox can illuminate the path to informed real estate solutions, visit us at: www.LightBoxRE.com

Media inquiries: media@lightboxRE.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/lightbox-cre-march-index-posts-strongest-reading-since-2022-but-outlook-remains-uncertain-302422286.html

SOURCE LightBoxRE

Continue Reading

Technology

Dark Horse CPAs Promotes Matthew Reese, CPA to Principal After 4-Month, $400K+ Success

Published

on

By

Reese Completes Principal Accelerator Program, establishes SMB Accounting and Tax Practice in Orlando, Florida

ORLANDO, Fla., April 7, 2025 /PRNewswire/ — Dark Horse CPAs, a top accounting and tax firm serving small businesses and individuals across the nation, announces the promotion of Matthew Reese to Principal. Reese’s noteworthy technical skills and rapid growth of his book of business, bolstered by strong relationships with clients and colleagues alike earned him a seat at the table, becoming an equity Principal of the firm.

Matthew entered the Dark Horse Principal Accelerator Program in July 2024 and built a tax and accounting practice with recurring revenue north of $400,000 in four months’ time. Far from being a volume play, he was able to achieve this revenue figure with a surprisingly small number of clients.  Given the overwhelming positive client feedback, high quality work and positive collaboration with his peers, the decision was made to promote him to Principal effective November 2024.

Speaking to the challenges posed by the Accelerator Program, Matthew stated, “the most challenging aspect of the journey was developing the confidence and assertiveness to command the value I bring to client engagements in terms of the price and scope in my proposals. Waiting on those initial proposals was difficult as I was unsure if prospects would sign while I was anxious to embark on the work of building my practice. Not rushing the process nor conceding on price just to get the work in the door has already shown itself to be the solid foundation on which to build a great practice with intention vs the haphazard, chaotic practices that many practitioners begin their journey with.”

When asked about the most rewarding aspect of his journey in the Accelerator Program, he continued his previous thought, “it was securing my first client. It proved that I could do this and it felt great to feel the trust and confidence they conveyed to me.” In terms of what differed most from his expectations of the Accelerator Program, he continued, “the biggest surprise was that fellow Accelerators and Principals celebrated this win, and others, alongside me. Rather than competing, everyone is very supportive and celebrates each other’s successes. Naturally, this creates a truly collaborative environment that we all benefit from.”

As to what he would want other potential Accelerators to know about the Program, Reese believes they should know, “the learning and growth, particularly in sales, is absolutely invaluable. Far from being trapped in a corporate machine, you quickly realize the Program is about self-actualization as a professional and as a human. I would wholeheartedly recommend anyone who has the itch to start a practice strongly consider becoming a Dark Horse Accelerator.”

Moving forward, Matthew is excited to, “develop a specialized niche in Esports with the backing of a firm that fully supports my vision to innovate and build within the space.”

“As I came to know Matt and started to hear feedback from clients and friends who were working with him, I had one of those rare moments,” says Chase Birky, CEO & co-founder of Dark Horse CPAs. “A rare moment, for me anyway, of taking stock of how far we’ve come as a firm. That we could attract someone of his caliber and that his success could come so quickly was humbling. It’s exactly what we hoped the Principal Accelerator Program would look like. And he is exactly the type of CPA we want to build this firm and this community around. So, yeah, I’m excited to support and bare witness to his journey in building a differentiated practice that allows him to pursue his interests and build a great life in the process.”

About the Dark Horse Accelerator Program

The Dark Horse Principal Accelerator Program was created for entrepreneurially-minded CPAs that want to build a scalable book of business without the personal and financial sacrifices required of starting a firm from scratch. Dark Horse empowers their CPAs with the resources and support to grow intelligently and profitably. Their proprietary technology, flexible staffing and industry-leading systems and processes enable CPAs to focus on being the trusted advisor to their clients, unlocking unprecedented value in these relationships, so that they will continue to be relevant long into the future while their counterparts become increasingly displaced by technology.

Accelerators are put through a training program that acclimates them to the firm’s exclusive tech stack, followed by proprietary sales training and one-on-one coaching. Upon completion of training, they begin building their book of business by fielding inquiries from potential Dark Horse clients. To facilitate their growth, Accelerators have full-time and fractional professional personnel support at their disposal. A collaborative group of like-minded CPAs go the extra mile to help them out in areas where they lack expertise. This new CPA firm business model includes an active corporate team that ensures their work is of high quality and strategically focused. After successful completion of the program, they can become an equity principal of the firm.

The Dark Horse Principal Accelerator Program is currently accepting new Accelerators. Interested CPAs are invited to dive deeper into the program on Dark Horse’s recruiting site, abetterway.cpa

Dark Horse CPAs provides integrated tax, accounting and wealth advisory services to small businesses and individuals across the U.S. The firm was founded to save small businesses (and their owners) from subpar accounting and tax services and subpar client experiences. These small businesses are Dark Horses among their larger and more well-known competition. Being a Dark Horse CPA means advocating for small businesses by bringing to them the tax strategies and accounting insights previously reserved for big business. To learn more, visit Dark Horse CPAs https://abetterway.cpa/ 

View original content to download multimedia:https://www.prnewswire.com/news-releases/dark-horse-cpas-promotes-matthew-reese-cpa-to-principal-after-4-month-400k-success-302422301.html

SOURCE Dark Horse CPAs

Continue Reading

Trending